Serum GFAP – pediatric reference interval in a cohort of Danish children

Tybirk, Lea; Hviid, Claus Vinter Bødker; Knudsen, Cindy Soendersoe; Parkner, Tina

doi:10.1515/cclm-2023-0280

Cited by 6 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, no physiological reference values have been established to date for children in regards to UCH-L1, and only one recent study has proposed a paediatric reference interval for GFAP, in a cohort of Danish children. 35 As with other brain biomarkers, 36 it has been shown that age can influence their concentrations and that GFAP levels after severe trauma were higher in a paediatric cohort than in adults. 31 The overall aim of the BRAINI-2 paediatric study is to provide new knowledge regarding GFAP and UCH-L1 in children and adolescents in order to improve TBI management in the paediatric population.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 98%

Performance of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) biomarkers in predicting CT scan results and neurological outcomes in children with traumatic brain injury (BRAINI-2 paediatric study): protocol of a European prospective multicentre study

Lorton,

Lagares,

de la Cruz

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionIn light of the burden of traumatic brain injury (TBI) in children and the excessive number of unnecessary CT scans still being performed, new strategies are needed to limit their use while minimising the risk of delayed diagnosis of intracranial lesions (ICLs). Identifying children at higher risk of poor outcomes would enable them to be better monitored. The use of the blood-based brain biomarkers glial fibrillar acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) could help clinicians in this decision. The overall aim of this study is to provide new knowledge regarding GFAP and UCH-L1 in order to improve TBI management in the paediatric population.Methods and analysisWe will conduct a European, prospective, multicentre study, the BRAINI-2 paediatric study, in 20 centres in France, Spain and Switzerland with an inclusion period of 30 months for a total of 2880 children and adolescents included. To assess the performance of GFAP and UCH-L1 used separately and in combination to predict ICLs on CT scans (primary objective), 630 children less than 18 years of age with mild TBI, defined by a Glasgow Coma Scale score of 13–15 and with a CT scan will be recruited. To evaluate the potential of GFAP and UCH-L1 in predicting the prognosis after TBI (secondary objective), a further 1720 children with mild TBI but no CT scan as well as 130 children with moderate or severe TBI will be recruited. Finally, to establish age-specific reference values for GFAP and UCH-L1 (secondary objective), we will include 400 children and adolescents with no history of TBI.Ethics and disseminationThis study has received ethics approval in all participating countries. Results from our study will be disseminated in international peer-reviewed journals. All procedures were developed in order to assure data protection and confidentiality.Trial registration numberNCT05413499.

show abstract

Section: Strengths and Limitations Of This Studymentioning

confidence: 98%

Performance of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) biomarkers in predicting CT scan results and neurological outcomes in children with traumatic brain injury (BRAINI-2 paediatric study): protocol of a European prospective multicentre study

Lorton,

Lagares,

de la Cruz

et al. 2024

BMJ Open

View full text Add to dashboard Cite

show abstract

Plasma concentrations of glial fibrillary acidic protein, neurofilament light, and tau in Alexander disease

Ashton,

Di Molfetta,

Tan

et al. 2024

Neurol Sci

View full text Add to dashboard Cite

Introduction Alexander disease (AxD) is a rare leukodystrophy caused by dominant gain-of-function mutations in the gene encoding the astrocyte intermediate filament, glial fibrillary acidic protein (GFAP). However, there is an urgent need for biomarkers to assist in monitoring not only the progression of disease but also the response to treatment. GFAP is the obvious candidate for such a biomarker, as it is measurable in body fluids that are readily accessible for biopsy, namely cerebrospinal fluid and blood. However, in the case of ASOs, the treatment that is furthest in development, GFAP is the target of therapy and presumably would go down independent of disease status. Hence, there is a critical need for biomarkers that are not directly affected by the treatment strategy. Methods We explored the potential utility of biomarkers currently being studied in other neurodegenerative diseases and injuries, specifically neurofilament light protein (NfL), phosphorylated forms of tau, and amyloid-β peptides (Aβ42/40). Results and Conclusions Here, we report that GFAP is elevated in plasma of all age groups afflicted by AxD, including those with adult onset. NfL and p-tau are also elevated, but to a much lesser extent than GFAP. In contrast, the levels of Aß40 and Aß42 are not altered in AxD.

show abstract

Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population

Cooper,

Stukas,

Ghodsi

et al. 2023

Clinical Biochemistry

View full text Add to dashboard Cite

Serum GFAP – pediatric reference interval in a cohort of Danish children

Cited by 6 publications

References 45 publications

Performance of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) biomarkers in predicting CT scan results and neurological outcomes in children with traumatic brain injury (BRAINI-2 paediatric study): protocol of a European prospective multicentre study

Performance of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) biomarkers in predicting CT scan results and neurological outcomes in children with traumatic brain injury (BRAINI-2 paediatric study): protocol of a European prospective multicentre study

Plasma concentrations of glial fibrillary acidic protein, neurofilament light, and tau in Alexander disease

Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population

Contact Info

Product

Resources

About